Welcome to our dedicated page for Quipt Home Medical news (Ticker: QIPT), a resource for investors and traders seeking the latest updates and insights on Quipt Home Medical stock.
Quipt Home Medical Corp. (QIPT) generates a steady flow of news as a U.S.-based home medical equipment provider focused on end-to-end respiratory care and in-home chronic disease management. Company press releases regularly discuss its role in providing in-home monitoring and disease management services for patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions in the United States healthcare market.
News coverage for QIPT commonly includes financial results and operational updates. For example, Quipt issues quarterly and annual earnings releases that highlight revenue trends, recurring revenue from equipment rentals and respiratory resupplies, Adjusted EBITDA, and operational metrics such as the number of unique patients served and set-ups or deliveries completed. These releases often include management commentary on business performance, revenue stabilization, and the contribution of acquisitions and partnerships.
Another major category of Quipt news involves strategic transactions. The company has announced acquisitions of durable medical equipment providers and a joint venture interest in Hart Medical Equipment, as well as a preferred provider agreement with Ballad Health. These items describe how Quipt works with health systems and hospitals to integrate home medical equipment and respiratory care into hospital discharge processes and post-acute care coordination.
More recently, Quipt’s news has featured corporate and M&A developments, including activist shareholder commentary and, most notably, the December 2025 announcement of a definitive Arrangement Agreement under which a special purpose acquisition vehicle funded by affiliates of Kingswood Capital Management and Forager Capital Management will acquire all outstanding Quipt shares for cash. This transaction, if completed, is expected to result in Quipt becoming a privately held company and its shares being delisted from The Nasdaq Capital Market and the Toronto Stock Exchange.
Investors and observers using this QIPT news page on Stock Titan can review these earnings announcements, acquisition and joint venture updates, health system partnership news, and transaction-related disclosures in one place, helping them understand how Quipt’s home medical equipment and respiratory care strategy is reflected in its public communications.
Quipt Home Medical, a leading U.S. based home medical equipment provider specializing in end-to-end respiratory care, has scheduled its fiscal Second quarter 2025 financial results announcement for May 12, 2025, after market close.
The company's leadership team, including CEO Gregory Crawford and CFO Hardik Mehta, will host a conference call for the investment community on May 13, 2025 at 10:00 a.m. ET. Investors can join via:
- Canada/US Toll Free: 1 (833) 752 3722
- International: 1 (647) 846 8549
A live webcast will be available through the investor section of Quipt's website at www.quipthomemedical.com.
Quipt Home Medical Corp. (NASDAQ: QIPT) has announced its strategic priorities for 2025, focusing on enhancing shareholder value through multiple initiatives. The company plans to accelerate organic growth by expanding De Novo locations, following successful openings in Florida and Alabama, and deepening referral networks with healthcare providers.
Key strategic priorities include implementing a share repurchase program through Normal Course Issuer Bid (NCIB), reflecting confidence in the company's fundamentals. Quipt is also pursuing strategic M&A opportunities with healthcare systems through potential joint ventures and acquisitions, aiming to integrate home-based care within larger healthcare ecosystems.
The company is launching the Quipt Sales Accelerator program for advanced sales training and expanding its product portfolio with new respiratory offerings. At its Annual General Meeting, shareholders approved the re-appointment of BDO USA as auditor and elected four directors. The board approved grants of 425,000 stock options at US$2.37 per share and 2,478,753 restricted stock units under its 2024 Equity Incentive Plan.
Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, has announced a cooperation agreement with Kanen Wealth Management. Under this agreement, Kanen has withdrawn its intent to solicit proxies for four director candidates at the 2025 annual general meeting.
The agreement grants Kanen Board access rights while maintaining at least 3.5% ownership of outstanding shares, including quarterly discussions with the Board Chairman or non-executive director. A new Board committee will be established to review Kanen's recommendations on corporate governance and operations.
The agreement includes a customary standstill and voting commitment from Kanen. DLA Piper, Vinson & Elkins L.L.P., and Goodmans LLP serve as legal advisors, with Longacre Square Partners as strategic advisor.
Quipt Home Medical (NASDAQ: QIPT) reported Q1 2025 financial results with revenue of $61.4 million, down 2% from Q1 2024's $62.6 million. The company faced challenges including the discontinuation of Medicare 75/25 blended rate, withdrawal of Medicare Advantage members, and non-renewal of a disposable supply contract, with a cumulative annual impact of approximately $8.0 million.
Key metrics include: net loss improvement to ($1.1) million or ($0.03) per share, operating cash flow of $9.3 million, and Adjusted EBITDA of $14.0 million (22.8% of revenue). The company maintains strong recurring revenue at 77% of total revenue and serves approximately 157,000 unique patients, a 1% year-over-year increase.
The company completed 221,000 unique set-ups/deliveries in Q1 2025, up 3% from Q1 2024, with 124,000 respiratory resupply set-ups/deliveries. Quipt operates across 140+ locations with approximately 36,000 referring physicians.
Quipt Home Medical Corp. (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider specializing in respiratory care, has received a proxy solicitation notice from Philotimo Fund, LP, affiliated with Kanen Wealth Management, (KWM). The notice indicates KWM's intention to nominate four director candidates to Quipt's Board of Directors in opposition to the company's candidates.
The company's Board and Nominating and Corporate Governance Committee will review KWM's notice for compliance with company Articles and applicable laws. Lead Independent Director Mark Greenberg emphasized the company's commitment to executing their strategic growth plan and maintaining high corporate governance standards. The company states it has delivered consistent performance despite challenging industry conditions.
Quipt notes that it has not received a timely, valid, and compliant director nomination notice under U.S. securities laws and company Articles. No immediate shareholder action is required.
Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider specializing in end-to-end respiratory care, has scheduled the release of its fiscal first quarter 2025 financial results for Monday, February 10, 2025, after market close.
The company will hold a conference call for investors on Tuesday, February 11, 2025, at 10:00 a.m. (ET), hosted by CEO Gregory Crawford and CFO Hardik Mehta. Participants can join via Canada/US Toll Free at 1 (844) 763 8274 or International at 1 (647) 484 8814. A live webcast will be available through the investor section of Quipt's website.
Quipt Home Medical (NASDAQ: QIPT) reported its fiscal year 2024 financial results, posting revenue of $245.9 million, a 16.2% increase from 2023's $211.7 million. The company achieved organic growth of $7.1 million (3%) and maintained strong recurring revenue at 78% of total revenue. Adjusted EBITDA reached $57.9 million (23.5% margin) compared to $50.6 million in 2023.
Q4 2024 revenue was $61.3 million, up 3% from Q4 2023, with sequential organic growth of 1%. The company faced challenges including a Medicare 75/25 relief pause and a cyberattack on Change Healthcare, impacting revenue by approximately $5 million and $3 million respectively. The customer base grew 4% year-over-year to 153,000 unique patients, with completed set-ups/deliveries increasing 13% to 854,000.
FAQ
What is the current stock price of Quipt Home Medical (QIPT)?
What is the market cap of Quipt Home Medical (QIPT)?
